Page last updated: 2024-10-23

atenolol and Hyperuricemia

atenolol has been researched along with Hyperuricemia in 3 studies

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.

Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.

Research Excerpts

ExcerptRelevanceReference
"We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus."5.14Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Manrique, C1
Johnson, M1
Sowers, JR1
Cooper-DeHoff, RM1
Wen, S1
Beitelshees, AL1
Zineh, I1
Gums, JG1
Turner, ST1
Gong, Y1
Hall, K1
Parekh, V1
Chapman, AB1
Boerwinkle, E1
Johnson, JA1
Sidorenko, BA1
Ugriumova, MO1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519]Phase 41,701 participants (Actual)Interventional2005-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)).

(NCT00246519)
Timeframe: baseline to 18 weeks of treatment

InterventionmmHg (Mean)
Atenolol +HCTZ Arm-12.06
HCTZ + Atenolol-13.33

Reviews

1 review available for atenolol and Hyperuricemia

ArticleYear
[New perspectives of the use of angiotensin II receptor blocker].
    Kardiologiia, 2003, Volume: 43, Issue:6

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit

2003

Trials

1 trial available for atenolol and Hyperuricemia

ArticleYear
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
    Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina

2010

Other Studies

1 other study available for atenolol and Hyperuricemia

ArticleYear
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
    Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:1

    Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast

2010